Neon’s next steps

Neon plans to deploy its $70M B round across three neoantigen programs

Neon Therapeutics Inc.’s $70 million B round gives the company enough fuel to run three neoantigen programs in parallel.

Partner Fund Management led the round, which closed on Jan. 5. Additional new investors Fidelity Management and Research Co., Wellington

Read the full 386 word article

User Sign In